Rituximab for aggressive B-cell lymphoma - horizon scanning review

Record ID 32002000546
Authors' objectives:

To summarise the current research evidence on rituximab for aggressive B-cell lymphoma.

Authors' recommendations: - Clinical impact: An estimated 3,400 people present with aggressive NHL per year. Rituximab is a complementary treatment with the potential to reduce mortality. The side effects of rituximab will probably not add significantly to the adverse effects experienced by patients undergoing CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy. - Service impact: There will be little additional impact on the current services. - Additional factors: Patients and carers will welcome an additional drug that increases survival. - Financial and overall NHS impact: The cost of rituximab is not insignificant and is additional to current treatment. If all the estimated 3,700 patients were given rituximab the drug costs would increase by up to 33.2M GBP. This amount will increase, if patients who relapse after rituximab/CHOP are re-treated.
Authors' methods: Overview
Project Status: Completed
Year Published: 2002
URL for published report: http://www.hsric.nihr.ac.uk/search
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Lymphoma, B-Cell
Organisation Name: NIHR Horizon Scanning Centre
Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name: c.packer@bham.ac.uk
Contact Email: c.packer@bham.ac.uk
Copyright: National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.